Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 412-720-6 | CAS number: 156653-67-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 21 April 1993 to 19 May 1993
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted to OCED test guidance in compliance with GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 993
- Report date:
- 1993
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Details on test material:
- See below
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test species: Wistar rat
Strain: Hoe: WISKf(SPF71)
Origin: HOECHST AG, Kastengrund, SPF breeding colony
Age at start of study: approx. 6 weeks
Animal maintenance: in fully air-conditioned rooms in Makrolon cages (Type 4) on soft wood granulate in groups of 5 animals
Room temperature: 22 ± 3⁰C
Relative humidity: 50 ± 20 %
Lighting time: 12 hours daily
Acclimatization: approx. 5 days
Food: Altromin 1324 rat diet (Altromin GmbH, Lage/Lippe), ad libitum except for the period in which the animals were kept in diuresis cages
Water: tap water in plastic bottles, ad libitum except for the period in which the animals were kept in diuresis cages
Animal identification: fur-marking with KMn04, numbered ear tags and cage numbering
Randomisation: Allocation of animals to cages: Randomisation tables 93.177 and 93.178 (detailed in the report).
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- deionised
- Details on oral exposure:
- Route of application: orally gavage
Vehicle: deionised water - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Not applicable.
- Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 62.5, 250, 1000 mg/kg bw/d
Basis:
actual ingested
- No. of animals per sex per dose:
- Treatment group Dose
(mg/kg bw./d) No. of animals Animal Nos.
Male Female Male Female
1 0 5 5 1-5 21-25
2 62.5 5 5 6-10 26-30
3 250 5 5 11-15 31-35
4 1000 5 5 16-20 36-40 - Control animals:
- yes, concurrent no treatment
- Details on study design:
- Rationale for dose-selection:
Testing of Reaktiv-Gelb F-66 923 FW for acute oral toxicity in the Wistar rat yielded a median lethal dose above 2000 mg/kg bodyweight. After application of 2000 mg/kg bodyweight the animals showed squatting posture, stilted gait as well as mucous and yellow discoloured feces. No signs of intoxication were observed one day after application.
Based on these results Reaktiv-Gelb F-66 923 FW was tested in the present study at the dose levels of 0, 62.5, 250 and 1000 mg/kg body weight per day.
Rationale for the route of exposure: The oral route is considered to be a potential exposure route in man.
Rationale for species selection: The Wistar rat has proved to be a suitable species for subacute oral toxicity testing with many different substances. - Positive control:
- None.
Examinations
- Observations and examinations performed and frequency:
- Behaviour and State of health
The behaviour and general health condition of the animals were observed twice daily, and at weekends and on public holidays once daily. The animals were examined weekly for neurological disturbances, opacity of the refracting media of the eyes, damage to the oral mucosa and impairment of dental growth.
Body weight
The body weights of all animals were determined at the start of the study and then twice weekly throughout the study.
Food and water consumption
Food consumption was determined continuously (2 times per week). The values on the printouts refer to the intervals between one measurement and the next. They are converted to the food consumption per 100 g bodyweight over a 24 hour period.
Water consumption was determined once weekly over a period of 16 hours and is given in the results as water consumption / animal / 16 h (from 3.15 p.m. to 7.15 a.m.)
Hematological investigations
At the termination of the study, hematological examinations were performed on all animals without previous withdrawal of food. Blood samples were taken from the retroorbilal venous plexus in narcosis (intraperitoneal injection of 50 -100 mg Ketamin / kg bodyweight). In order to prevent systematic errors, blood sampling was conducted in a randomised order.
The following hematological parameters were determined:
Erythrocyte count, Hemoglobin, Hematocrit, Mean cellular volume (MCV), Mean cellular haemoglobin (MCH), Mean cellular haemoglobin concentration (MCHC), Leucocyte count, Thrombocyte count, Differential leucocyte count and red cell morphology count*, Heinz bodies*, Coagulation time.
*These parameters were scored only in animals of the control and high dose group.
Clinical Chemistry
After blood sampling for hematological testing, the animals were killed by cutting of the vena cava cranial is in deep narccsis and exsanguinated. In order to prevent systematic errors, exsanguination was conducted in a randomised order.
The following serum values were determined:
Sodium,Potassium, Inorganic phosphorus, Uric acid, Bilirubin total, Creatinine, Serum-glucose, Urea nitrogen, Chloride, Aspartate aminotransferase (ASAT/G0T), Alanine aminotransferase (ALAT/GPT), Alkaline phosphatase (AP), Gamma-glutamyltransferase (GGT), Cholesterol, Triglycerides, Total protein, Albumin.
Urine analysis
Urine analysis was performed on all animals a few days before termination of the study, for this purpose, the urine was collected by using metabolism cages (overnight night from day 26 to 27).
The following parameters were checked:
Appearance, Colour, pH-Value, Hemoglobin, Protein, Glucose, Ketone bodies, Bilirubin, UrobiIinogen, Specific Weight, Sediment*, Volume.
*These parameters were scored only in the control and high dose group - Sacrifice and pathology:
- Necropsy and macroscopic, examination
After exsanguination, all animals were necropsied in accordance with the Dissection Schedule I of the Department for Pathology and checked for macroscopically visible abnormalities. The autopsy included macroscopic examination of the skin, orifices, eyes, teeth, oral mucosa and internal organs. All abnormal findings were recorded.
Organ weights
The following organs were weighed and the organ to body weight ratio calculated:
Heart, Liver, Kidneys, Ovaries, Spleen, Adrenals, Testes, Epididymides.
Histopatholoqy
The following tissues or organs (or pieces of them) were preserved in a suitable fixative in accordance with the Dissection Schedule of the Department for Pathology and processed for histopathological investigations:
Heart, Liver, Kidneys, Adrenals, Spleen, Testes, Stomach, Jejunum, Colon, Uterus, Ovaries, Epididymides - Statistics:
- The following parameters were compared statistically with the control group values at the level of significance p = 0.05:
Body weights at the designated measurement times
Hematological data
Clinical chemistry parameters
Urine analysis (Volume, pH-value and specific weight) Absolute organ weights and organ to body weight ratios
Evaluation was performed by Pharma Research and Development Informatics with the aid of a program package for the evaluation of toxicological studies, according to the respective standard operating procedures. The calculation methods used are referred to are detailed in their entirety within the report..
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Behaviour, state of health and mortality
Behaviour and general health condition of the animals remained normal throughout the study.
Compound-related neurological disturbances, opacity of the refracting media of the eyes, impairment of dental growth or changes of the oral mucosa were not observed .
No deaths occurred throughout the study.
Body weight gain
Body weight development was not impaired by the administration of the test compound and was comparable in all groups.
Body weights were increased to a statistically significant degree in males of all treatment groups (low dose: day 6 until day 13; intermediate and high dose: day 1 until day 16).
Females of the high dose group showed statistically significant decreases in bodyweights before the start of the study.
Food and water consumption
Absolute and relative food consumption remained normal throughout the study.
Likewise, the administration of the test compound did not alter absolute or relative water consumption.
Hematological investigations
Statistical evaluation revealed increases in coagulation times in males of the intermediate and high dose group. There was no typical dose-dependency. Furthermore, the changes were only small and occurred in one sex only. Therefore, a compound-related effect is not directly evident. However, no adverse effects were observed in these animals.
Furthermore, hemoglobin levels were increased to a statistically significant degree in females of the high dose group. These values were within the normal range of the rat strain used [126-163 g/l] and low hemoglobin concentrations were measured in females of the control group. Therefore, a compound-related effect is unlikely.
Heinz bodies were not detected. Evaluation of differential white cell count revealed no abnormalities.
Clinical chemistry
Statistical evaluation revealed decreases in sodium and bilirubin values as well as increases in triglyceride concentrations in males of the high dose group. All values were within the normal range of the rat strain used [sodium; 135-151 mmoi/l; bilirubin: 1.3-6.1 umol/l; triglycerides: 0.52-2.67 mmol/l]. Furthermore, the changes occurred in one sex only. Therefore, a compound-related effect is not directly evident. However, no adverse effects were noted in these animals.
Females of the low dose group showed statistically significant increases in protein and albumin levels. As there was no dose-dependency, a compound-related effect can be ruled out.
Urine analysis
Examination of the urinary status revealed no compound-related effects, the sediments were inconspicuous.
Organ weights
Liver and kidney weights were increased in males of the intermediate and high dose group. There was no typical dose-dependency. Furthermore, these changes occurred in one sex only and there was no evidence for an impairment of liver or kidney function, neither by clinical chemistry nor by histopathology. Therefore, a compound-related effect is not evident.
Heart weights were increased to a statistically significant degree in males of the intermediate dose group. As there was no dose-dependency, a compound-related effect is unlikely.
Macroscopic and microscopic findings
No compound-related effects were observed at necropsy.
Histopathological examinations revealed no compound-related effects.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In conclusion Reaktiv-Gelb F-66 923 FW caused no detectable adverse effects in male and female Wistar rats when administered 28 times during 29 days. With regard to the present study the 'no observed adverse effect level' is 1000 mg/kg bodyweight per day.
- Executive summary:
The present 28-day toxicity study was conducted in order to characterise the toxicological profile of Reaktiv-Gelb F-66 923 FW after repeated oral exposure. Additionally, the results of this study can be used as a dose-range-finding for subchronic and chronic feeding studies.
The present study was conducted in compliance with OECD Guidelines for Testing of Chemicals, 407 "Repeated Dose Oral Toxicity -Rodent: 28-day or14-day Study" and in compliance with the Principles of Good Laboratory Practice (GLP).
Groups of 5 male and 5 female Wistar rats received Reaktiv-Gelb F-66 923 FW by oral gavage at dose levels of 0, 52.5, 250 or 1000 mg/kg body weight per day for 28 days and were necropsied at day 29.
Behaviour and state of health were observed daily in all groups. Body weights and food consumption were recorded twice weekly, and water consumption once weekly.
Hematological examinations and clinical chemistry were carried out at the termination of the study. Urine analysis was also performed at the end of the study.
During necropsy the animals were examined for microscopically visible abnormalities, the main organs weighed and the organ to body weight ratios calculated. Many organs and tissues were processed for histopathological examination and checked for microscopically visible changes.
Body weights, hematological and clinical chemistry data, urine data (volume, pH value, specific weight), absolute and relative organ weights were analysed with the aid of a statistical program to show differences compared with the controls .
Behaviour, state of health, body weight development, food and water consumption were not affected by the administration of the test compound in males and females from all groups.
Urine analysis, hematological examinations and clinical chemistry showed no compound-related effects.
Organ weights were not affected by the administration of the test compound. No compound related macroscopically visible changes were found at necropsy. Likewise, histopathological examinations revealed no substance-related changes.
In conclusion Reaktiv-Gelb F-66 923 FW caused no detectable adverse effects in male and female Wistar rats when administered 28 times during 29 days. With regard to the present study the 'no observed adverse effect level' is1000 mg/kg bodyweight per day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Bien que l'ECHA fournisse énormément de matériel en ligne dans votre langue, une partie de cette page n'est disponible qu'en anglais. De plus amples informations sur la pratique multilingue de l'ECHA sont disponibles.
Bienvenue sur le site web de l'ECHA. Ce site n'est pas entièrement compatible avec Internet Explorer 7 (ni avec les versions antérieures). Veuillez mettre à jour Internet Explorer.
Ce site web utilise des cookies afin de vous garantir la meilleure expérience possible sur nos sites web.
Pour en savoir plus sur la façon dont nous utilisons les cookies.